Esperion Therapeutics Q2 2024 GAAP EPS $(0.33) Misses $(0.18) Estimate, Sales $73.834M May Not Be Comparable To $49.056M Estimate
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics reported a Q2 2024 GAAP EPS of $(0.33), missing the estimate of $(0.18). Sales were $73.834M, which may not be comparable to the $49.056M estimate.
August 12, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Esperion Therapeutics reported a Q2 2024 GAAP EPS of $(0.33), missing the estimate of $(0.18). Sales were $73.834M, which may not be comparable to the $49.056M estimate.
The significant miss on EPS is likely to negatively impact investor sentiment and the stock price in the short term. The sales figure, although higher, may not be directly comparable, adding uncertainty.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100